Generic erosion will reduce BPH/male urinary tract drug market to $4 billion in 2010

The market for therapies that treat benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms will fluctuate over the next decade as modest growth from 2013 to 2017 will be negated by a 7.1% annual decline from 2010 to 2013 and by a subsequent market decline from 2017 to 2020, according to advisory firm Decision Resources.

Owing to the generic erosion of key agents, the BPH drug market will decrease from more than $4.8 billion in 2010 to just under $4 billion in 2020 in the major markets of the USA, France, Germany, Italy, Spain, the UK and Japan.

The findings from DR’s Pharmacor topic titled Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms reveal that this market - which is saturated with effective, well-established treatments - is also concentrated as tamsulosin (Boehringer Ingelheim’s Flomax/Josir/Alna/Pradif/Urolosin, Astellas’ Omix/Omnic/Flomaxtra/Harnal, generics) dominated overall sales with a market share of 45% in 2010, despite extensive generic competition in the USA.